| Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. | |
| | |
MedLine Citation:
|
PMID: 12921486 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The incidence of clinically significant pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) ranges from 1-13.5%. It is more common after therapeutic procedures such as sphincterotomy or balloon dilatation of the sphincter, and diagnostic procedures such as biliary or pancreatic manometry. The severity of post-ERCP pancreatitis may vary from very mild to extremely severe disease with multiple organ failure and fatal outcome. Several factors including papillary oedema, injection of hyperosmolar contrast-material, introduction of previously activated enzymes during repeated cannulation, bacterial contamination and thermal injury from endoscopic sphincterotomy have been implicated as triggering factors that initiate the sequential cascade of pancreatic autodigestion and release of proinflammatory cytokines leading to acute pancreatitis. Recovery from post-ERCP pancreatitis is usually rapid when the injury is confined to the pancreas. However, systemic production of inflammatory mediators may lead to the development of more serious manifestations including multiorgan failure.A wide range of pharmacological agents has been tested in experimental and clinical trials, but the results have been largely disappointing. Several drugs are discussed in this review, but only somatostatin and gabexate (gabexate mesilate) have consistently shown a moderate beneficial effect. In clinical trials, both gabexate and somatostatin appear equally effective in reducing the incidence of pancreatitis by two-thirds compared with controls. However, both drugs need to be given by continuous infusion for about 12 hours and this makes them less cost-effective than conventional treatment. One potential strategy is to reserve these drugs for high-risk patients undergoing ERCP. Preliminary studies have shown encouraging results with nitroglycerin, antibacterials and heparin. However, these observations need to be corroborated in a rigorous fashion in large, randomised, double-blind, controlled trials. If these drugs are found to be effective in further trials, it may become cost-effective to use them routinely for the prevention of post-ERCP pancreatitis. Despite the theoretical benefits, interleukin-10 has not shown a consistent benefit in clinical trials. It is probable that other cytokine inhibitors or modulators may become available for future trials to prevent pancreatitis or more probably, to reduce the severity of pancreatitis. Further research also should focus on developing newer molecules or the use of a combination of currently available drugs to prevent pancreatitis in high-risk patients undergoing therapeutic ERCP procedures. |
| | |
Authors:
|
Hemant Pande; Paul Thuluvath |
Related Documents
:
|
15992666 - Tissue factor pathway inhibitor and antithrombin trial results. 8726596 - New pharmacologic approaches to acute spinal cord injury. 23595416 - Effect of counterion on the solid state photodegradation behavior of prazosin salts. 11750996 - World association for the advancement of veterinary parasitology (waavp): second editio... 17254956 - The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. 18186066 - A preliminary study on meo-peg-plga-peg-ome nanoparticles as intravenous carriers. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs Volume: 63 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 2003 |
Date Detail:
|
Created Date: 2003-08-18 Completed Date: 2004-02-10 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 1799-812 Citation Subset: IM |
Affiliation:
|
Division of Gastroenterology & Hepatology, The Johns Hopkins University School of Medicine, 1830 E. Monument Street, Baltimore, MD 21205, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Cholangiopancreatography, Endoscopic Retrograde / adverse effects* Clinical Trials as Topic Humans Pancreatitis / drug therapy*, etiology, prevention & control* Risk Factors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New molecular targets for treatment of peptic ulcer disease.
Next Document: Treatment of allergic rhinitis during pregnancy.